<DOC>
	<DOCNO>NCT03014622</DOCNO>
	<brief_summary>This safety efficacy study DaxibotulinumtoxinA Injection treat moderate severe frown line .</brief_summary>
	<brief_title>Efficacy Safety DaxibotulinumtoxinA Injection Treat Moderate Severe Glabellar Lines</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Provide write informed consent include authorization release health information Moderate ( 2 ) severe ( 3 ) glabellar line maximum frown base Investigator Global Assessment Frown Wrinkle Severity ( IGAFWS ) scale Moderate ( 2 ) severe ( 3 ) glabellar line maximum frown base Patient Frown Wrinkle Severity ( PFWS ) scale Willing able follow trial procedure , attend schedule visit , successfully complete trial Any neurological condition may place subject increase risk exposure botulinum toxin type A , include peripheral motor neuropathic disease amyotrophic lateral sclerosis motor neuropathy , neuromuscular junctional disorder LambertEaton syndrome myasthenia gravis Active skin disease , infection inflammation injection site Plan receive botulinum toxin type A anywhere face duration study History allergy sensitivity botulinum toxin preparation component test article Current enrollment investigational drug device trial participation trial within last 30 day prior screen end trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>glabellar line , frown line</keyword>
</DOC>